Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Cholangiocarcinoma
- Colorectal Carcinoma
- Esophageal Adenocarcinoma
- Gallbladder Carcinoma
- Gastric Adenocarcinoma
- GEJ Adenocarcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04430738
- Collaborators
- Not Provided
- Investigators
- Study Director: Christopher Lux, MD, PhD Seagen Inc.